Loncar Cancer Immunotherapy ETF (CNCR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Loncar Cancer Immunotherapy ETF (CNCR) trades at $9.02. Loncar Cancer Immunotherapy ETF (CNCR) is a non-diversified fund focused on investing in pharmaceutical and biotechnology companies developing cancer immunotherapies. Market cap: $7.04M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for CNCR: CNCR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CNCR against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on CNCR.
How is this calculated? →Loncar Cancer Immunotherapy ETF (CNCR) Financial Services Profile
Loncar Cancer Immunotherapy ETF (CNCR) provides targeted exposure to approximately 30 pharmaceutical and biotechnology companies at the forefront of cancer immunotherapy research and development. As a non-diversified fund, CNCR offers investors a concentrated investment vehicle within the rapidly evolving healthcare landscape, specifically within cancer treatment.
What Is the Investment Thesis for CNCR?
Loncar Cancer Immunotherapy ETF (CNCR) offers a targeted investment opportunity in the rapidly advancing field of cancer immunotherapy. The fund's value is driven by the success of its constituent companies in developing and commercializing innovative cancer treatments. Key growth catalysts include positive clinical trial results, regulatory approvals for new therapies, and increasing adoption of immunotherapies in cancer treatment protocols. With a beta of 0.96, CNCR exhibits market correlation. The fund's non-diversified nature presents both opportunities for outsized gains and potential risks associated with sector-specific downturns. The ETF's performance is closely tied to the progress and market acceptance of cancer immunotherapy, making it a focused, albeit potentially volatile, investment.
Based on FMP financials and quantitative analysis
CNCR Key Highlights
CNCR focuses on companies developing cancer immunotherapies, offering targeted exposure to this innovative field.
- The fund is non-diversified, concentrating its investments in approximately 30 pharmaceutical and biotechnology companies.
- CNCR aims to replicate the performance of an index composed of companies with a high strategic focus on cancer immunotherapy.
- The fund invests at least 80% of its total assets in the component securities of the index, ensuring alignment with its investment theme.
- CNCR has a market capitalization of $7.04M, reflecting its position as a niche ETF within the broader asset management landscape.
Who Are CNCR's Competitors?
CNCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BOB Alpha Architect Merlyn.AI Best-of-Breed Core Momentum ETF | $19.93 | +0.03% | $6.93M | 44 |
| GBDV Global Beta Smart Income ETF | $23.44 | -1.67% | $6.91M | 44 |
| JJM iPath Series B Bloomberg Industrial Metals Subindex Total Return ETN | $56.50 | +0.16% | $6.80M | 44 |
| LSLT Pacer Salt Low truBeta US Market ETF | $32.00 | -0.51% | $6.75M | — |
| LVUS Hartford Multifactor Low Volatility US Equity ETF | $28.55 | -0.03% | $7.14M | — |
| IDKFF ThreeD Capital Inc. | $0.07 | +13.85% | $6.98M | 70 |
| ALTEX Firsthand Alternative Energy Fund | $12.93 | -1.90% | $8.98M | 82 |
| BCG Binah Capital Group, Inc. | $1.40 | +0.72% | $23.5M | 78 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CNCR's Key Strengths?
Targeted exposure to a high-growth sector (cancer immunotherapy).
- Transparent investment strategy through index tracking.
- Potential for high returns driven by innovation in cancer treatment.
- Non-diversified structure allows for focused investment in leading immunotherapy companies.
What Are CNCR's Weaknesses?
Non-diversified nature increases volatility and risk.
- Performance is highly dependent on the success of the cancer immunotherapy sector.
- Subject to regulatory and clinical trial risks associated with pharmaceutical and biotechnology companies.
- Small market capitalization may limit liquidity.
What Could Drive CNCR Stock Higher?
Publication of clinical trial results for key immunotherapy drugs in CNCR's portfolio.
- Regulatory decisions on new immunotherapy applications by the FDA and other regulatory agencies.
- Increasing adoption of immunotherapies in cancer treatment protocols.
- Advancements in personalized immunotherapy approaches and combination therapies.
What Are the Key Risks for CNCR?
Clinical trial failures or regulatory setbacks for key immunotherapy drugs.
- Competition from other cancer treatment modalities.
- Pricing pressures and reimbursement challenges for new cancer therapies.
- Volatility in the biotechnology and pharmaceutical sectors.
- Non-diversified nature of the fund increases risk.
What Are the Growth Opportunities for CNCR?
- Expansion of Immunotherapy Applications: The increasing application of immunotherapy across various cancer types represents a significant growth opportunity for CNCR. As research continues to demonstrate the efficacy of immunotherapies in treating previously resistant cancers, the demand for these treatments is expected to rise, potentially driving the value of companies within the CNCR portfolio. The global immunotherapy market is projected to reach $250 billion by 2030, presenting a substantial opportunity for growth.
- Advancements in Combination Therapies: The development and approval of combination therapies, which pair immunotherapies with other cancer treatments like chemotherapy or targeted therapies, could further enhance the effectiveness of immunotherapy and expand its market reach. Companies within CNCR that are actively pursuing combination therapy research and development stand to benefit from this trend. The market for combination cancer therapies is expected to grow at a CAGR of 12% over the next five years.
- Regulatory Approvals and Market Access: Successful navigation of the regulatory approval process and securing market access for new immunotherapies are critical growth drivers for CNCR's constituent companies. Positive clinical trial results and favorable regulatory decisions can lead to significant revenue growth and increased market capitalization for these companies. The FDA's accelerated approval pathways for breakthrough therapies can expedite the commercialization of promising immunotherapies.
- Strategic Partnerships and Acquisitions: Strategic partnerships and acquisitions within the cancer immunotherapy space can create synergies, accelerate innovation, and expand market reach. Companies within CNCR that are actively pursuing such collaborations or are attractive acquisition targets may experience increased growth and value. The biopharmaceutical industry is witnessing a surge in M&A activity, with immunotherapy companies being highly sought after.
- Personalized Immunotherapy Approaches: The development of personalized immunotherapy approaches, tailored to individual patients' genetic profiles and cancer characteristics, represents a promising avenue for improving treatment outcomes and expanding the market for immunotherapy. Companies within CNCR that are investing in personalized medicine technologies and diagnostics stand to gain a competitive advantage. The personalized medicine market is projected to reach $500 billion by 2028, driven by advancements in genomics and precision diagnostics.
What Are CNCR's Competitive Advantages?
- Specialized Focus: CNCR's exclusive focus on cancer immunotherapy provides a differentiated investment offering.
- Index Tracking: The fund's strategy of tracking a specific index of immunotherapy companies offers transparency and predictability.
- Expertise: The fund's index provider possesses expertise in identifying and selecting companies with a high strategic focus on cancer immunotherapy.
What Does CNCR Do?
Loncar Cancer Immunotherapy ETF (CNCR) is designed to track the performance of an index composed of companies actively involved in the development of cancer immunotherapies. These companies are primarily pharmaceutical and biotechnology firms that are pioneering new treatments that leverage the body's own immune system to combat cancer. The fund was created to provide investors with a focused investment tool to capitalize on the growth and innovation within this specialized area of healthcare. CNCR invests in a portfolio of approximately 30 companies, carefully selected by the fund's index provider for their strategic emphasis on cancer immunotherapy. The fund's investment strategy involves allocating a significant portion, typically all or substantially all, of its assets into the component securities and American Depositary Receipts (ADRs) that constitute the underlying index. This approach ensures a high degree of alignment between the fund's performance and the performance of the targeted immunotherapy companies. As a non-diversified fund, CNCR concentrates its investments in a relatively small number of companies. While this strategy can potentially lead to higher returns if the immunotherapy sector performs well, it also exposes the fund to greater volatility and risk compared to more diversified investment vehicles. The fund adheres to a policy of investing at least 80% of its total assets in the component securities of the index, reinforcing its commitment to the cancer immunotherapy theme.
What Products and Services Does CNCR Offer?
- Invests in pharmaceutical and biotechnology companies.
- Focuses on companies developing cancer immunotherapies.
- Tracks the performance of an index of immunotherapy-focused companies.
- Allocates assets to component securities and ADRs of the index.
- Operates as a non-diversified fund.
- Aims to provide investors with targeted exposure to the cancer immunotherapy sector.
How Does CNCR Make Money?
- CNCR generates revenue through management fees charged to investors.
- The fund's performance is directly linked to the performance of its underlying investments in cancer immunotherapy companies.
- CNCR's business model relies on the continued growth and innovation within the cancer immunotherapy sector.
What Industry Does CNCR Operate In?
The asset management industry is characterized by a diverse range of investment vehicles, including ETFs like CNCR that target specific sectors or themes. The cancer immunotherapy market is experiencing rapid growth, driven by advancements in biotechnology and increasing demand for innovative cancer treatments. CNCR operates in a competitive landscape with other specialized ETFs and investment funds, including BOB (ProShares Ultra Nasdaq Biotechnology), GBDV (GraniteShares 1x Short Bloomberg Gold Daily ETF), JJM (iPath Series B Bloomberg Nickel Subindex Total Return ETN), LSLT (Direxion Daily Small Cap Bull 3X Shares), and LVUS (The Live Oak ESG US Dividend ETF), each offering different investment strategies and risk profiles. The success of CNCR depends on its ability to accurately track its underlying index and attract investors seeking exposure to the cancer immunotherapy sector.
Who Are CNCR's Key Customers?
- Individual investors seeking exposure to the cancer immunotherapy market.
- Institutional investors looking for targeted investment opportunities in the healthcare sector.
- Financial advisors seeking specialized ETFs for their clients' portfolios.
How Loncar Cancer Immunotherapy ETF Is Valued
Loncar Cancer Immunotherapy ETF carries a market capitalization of $7.04M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Loncar Cancer Immunotherapy ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. CNCR trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
CNCR Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to a high-growth sector (cancer immunotherapy).
- Transparent investment strategy through index tracking.
- Potential for high returns driven by innovation in cancer treatment.
- Non-diversified structure allows for focused investment in leading immunotherapy companies.
Bear Case
- Non-diversified nature increases volatility and risk.
- Performance is highly dependent on the success of the cancer immunotherapy sector.
- Subject to regulatory and clinical trial risks associated with pharmaceutical and biotechnology companies.
- Small market capitalization may limit liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
CNCR Latest News
No recent news available for CNCR.
CNCR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNCR.
Price Targets
Wall Street price target analysis for CNCR.
CNCR MoonshotScore
What does this score mean?
The MoonshotScore rates CNCR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
CNCR Financial Services Stock FAQ
What does Loncar Cancer Immunotherapy ETF do?
Loncar Cancer Immunotherapy ETF (CNCR) is a financial product designed to provide investors with targeted exposure to the burgeoning field of cancer immunotherapy. The ETF invests in a basket of approximately 30 pharmaceutical and biotechnology companies that are actively involved in the research, development, and commercialization of drugs and therapies that harness the body's own immune system to fight cancer.
What are the main risks for CNCR?
The primary risks associated with investing in CNCR stem from its concentrated focus on the cancer immunotherapy sector and its non-diversified structure. Clinical trial failures or regulatory setbacks for key immunotherapy drugs could significantly impact the performance of the ETF. Additionally, competition from other cancer treatment modalities and pricing pressures on new therapies could pose challenges.
How does CNCR's non-diversified structure impact its risk profile?
As a non-diversified fund, CNCR concentrates its investments in a relatively small number of companies, specifically those focused on cancer immunotherapy. This concentration can amplify both potential gains and potential losses. If the cancer immunotherapy sector performs well, CNCR may experience higher returns compared to more diversified investment vehicles.
How is Loncar Cancer Immunotherapy ETF adapting to changes in the biotechnology industry?
Loncar Cancer Immunotherapy ETF's adaptability to the biotechnology industry hinges on the index provider's ability to dynamically adjust the ETF's holdings to reflect the latest advancements and emerging trends in cancer immunotherapy. This includes incorporating companies that are pioneering new approaches, such as personalized immunotherapies or combination therapies, and removing companies that are lagging behind or facing significant challenges.
What are the key factors to evaluate for CNCR?
Evaluate CNCR on fundamentals, analyst consensus, and risk factors. Loncar Cancer Immunotherapy ETF (CNCR) offers a targeted investment opportunity in the rapidly advancing field of cancer immunotherapy. Not financial advice.
How frequently does CNCR data refresh on this page?
CNCR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CNCR's recent stock price performance?
Loncar Cancer Immunotherapy ETF (CNCR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted exposure to a high-growth sector (cancer immunotherapy). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CNCR overvalued or undervalued right now?
Loncar Cancer Immunotherapy ETF (CNCR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on publicly available sources and is intended for informational purposes only. It does not constitute investment advice.